Globus Medical to Acquire Nevro Corp. for $250 Million

Globus Medical (NYSE: GMED) and Nevro Corp. (NYSE: NVRO) have entered into a definitive agreement for Globus Medical to acquire all outstanding shares of Nevro in an all-cash transaction valued at approximately $250 million. The deal, unanimously approved by both companies' boards of directors, is set to enhance Globus Medical's position in musculoskeletal solutions and broaden its portfolio in chronic pain management.

The acquisition brings Nevro's technologies, which focus on neuromodulation and other pain relief solutions, under the Globus Medical umbrella. The company stated that the combination will allow for expanded market access and a deeper customer reach. Globus Medical CEO Dan Scavilla noted that the company's scale and operational capabilities will accelerate the market penetration of Nevro's technologies.

Nevro CEO Kevin Thornal expressed enthusiasm for the transaction, highlighting the opportunity to reach more patients globally and strengthen its position as a leader in pain management. Globus Medical anticipates the acquisition to be accretive to its earnings in the second year of operation.

The transaction represents a premium of approximately 17% over Nevro's closing market price on February 5, 2025. The deal is expected to close by the end of the second quarter of 2025, subject to approval from Nevro's shareholders, regulatory bodies, and other customary closing conditions.